Clinical trial
Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer
NCT00316199 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00316199 |
|---|---|
| Title | Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer |
| Official title | Phase II Study of Gemcitabine-Paclitaxel 3-Weekly Schedule as First-Line Treatment in Metastatic Breast Cancer After Anthracycline Failure |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine, paclitaxel |
| Enrollment | 60 |
| Start date | Apr 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Apr 20, 2006 |
| Last update posted | Jun 17, 2009 |
| Countries | China |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: